Stock AVTX AVALO THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Avalo Therapeutics, Inc.

Equities

AVTX

US05338F3064

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-04-26 EDT 		5-day change 1st Jan Change
15.94 USD +6.41% Intraday chart for Avalo Therapeutics, Inc. +37.06% +75.16%
04-17 North American Morning Briefing : Stock Futures -2- DJ
04-16 Oppenheimer Upgrades Avalo Therapeutics to Outperform From Perform, Price Target is $35 MT

Evolution of the average Target Price on Avalo Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

e6137d.hb1HhJimJS9tjxW9YVTA3L5O-U2G3ZtfaXbRUqPO-J0.6t4289LcHH8utl7zFTiakskRjSP8rdQ8HznoPZe-vdPf_A7V9spmcATlYg~69a20f393bf09ff7d114fc44e78c2e5c

Analyst Recommendations on Avalo Therapeutics, Inc.

Oppenheimer Upgrades Avalo Therapeutics to Outperform From Perform, Price Target is $35 MT
Oppenheimer Downgrades Avalo Therapeutics to Perform From Outperform, Removes $10 Price Target MT
Avalo Therapeutics Downgraded by RBC to Sector Perform From Outperform, Price Target Cut to $0.75 From $9, Speculative Risk Kept MT
RBC Cuts Price Target on Avalo Therapeutics to $9 From $17, Maintains Outperform Rating, Speculative Risk Qualifier MT
Jefferies Downgrades Avalo Therapeutics to Underperform From Hold, Lowers Price Target to $3 From $4.50 MT
Oppenheimer Adjusts Avalo Therapeutics Price Target to $10 From $17, Maintains Outperform Rating MT
Oppenheimer Adjusts Avalo Therapeutics Price Target to $17 From $5, Maintains Outperform Rating MT
RBC Cuts Price Target on Avalo Therapeutics to $17 From $21, Maintains Outperform Rating, Speculative Risk Qualifier MT
RBC Cuts Price Target on Avalo Therapeutics to $21 From $24 After 1-for-12 Reverse Stock Split; Outperform, Speculative Risk Kept MT
RBC Halves Price Target on Avalo Therapeutics to $2 From $4, Noting 'Early Stage Risk With Minimal Safeguards,' Keeps Outperform-Speculative Risk Rating MT
Jefferies Downgrades Avalo Therapeutics to Hold from Buy, Adjusts Price Target to $0.75 from $5 MT
RBC Cuts Price Target on Avalo Therapeutics to $4 From $5, Maintains Outperform Rating, Speculative Risk Qualifier MT
Oppenheimer Adjusts Avalo Therapeutics PT to $5 From $7, Maintains Outperform Rating MT
AVALO THERAPEUTICS : RBC Initiates Avalo Therapeutics With Outperform Rating, Speculative Risk Qualifier, Sets Price Target at $6 MT
CERECOR : Cantor Fitzgerald Initiates Coverage on Cerecor With Overweight Rating, $7 Price Target MT
CERECOR : Oppenheimer Adjusts Cerecor PT to $7 From $9 on Q1 Results and Ahead of Top-Line Data, Maintains Outperform Rating MT
CERECOR : Maxim Upgrades Cerecor to Buy from Hold, Sets $7 Price Target MT
CERECOR : Jefferies Initiates Cerecor at Buy with $4 Price Target MT
CERECOR : Oppenheimer Adjusts Cerecor PT to $9 From $10, Maintains Outperform Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
15.94 USD
Average target price
35 USD
Spread / Average Target
+119.57%
High Price Target
35 USD
Spread / Highest target
+119.57%
Low Price Target
35 USD
Spread / Lowest Target
+119.57%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Avalo Therapeutics, Inc.

Oppenheimer
RBC Capital Markets
Jefferies & Co.
Cantor Fitzgerald
Maxim

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. AVTX Stock
  4. Consensus Avalo Therapeutics, Inc.